Ionis Pharmaceuticals (NASDAQ:IONS) Upgraded to Hold at StockNews.com

StockNews.com upgraded shares of Ionis Pharmaceuticals (NASDAQ:IONS) from a sell rating to a hold rating in a research note published on Monday.

Several other research firms have also recently weighed in on IONS. Guggenheim reduced their price objective on Ionis Pharmaceuticals from $70.00 to $65.00 and set a “buy” rating for the company in a research report on Wednesday, October 9th. The Goldman Sachs Group upped their price target on Ionis Pharmaceuticals from $33.00 to $37.00 and gave the company a “sell” rating in a report on Friday, August 2nd. BMO Capital Markets lowered Ionis Pharmaceuticals from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $67.00 to $60.00 in a report on Friday, August 2nd. Leerink Partnrs raised Ionis Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, July 24th. Finally, Jefferies Financial Group began coverage on shares of Ionis Pharmaceuticals in a research note on Tuesday, July 16th. They set a “buy” rating and a $75.00 price target on the stock. One investment analyst has rated the stock with a sell rating, six have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $60.71.

Ionis Pharmaceuticals Stock Down 1.5 %

Ionis Pharmaceuticals stock opened at $38.46 on Monday. The company has a debt-to-equity ratio of 4.67, a current ratio of 7.61 and a quick ratio of 7.51. Ionis Pharmaceuticals has a fifty-two week low of $35.95 and a fifty-two week high of $54.44. The firm has a fifty day moving average price of $40.82 and a two-hundred day moving average price of $42.93. The firm has a market cap of $5.62 billion, a price-to-earnings ratio of -15.26 and a beta of 0.39.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.95) earnings per share for the quarter, topping the consensus estimate of ($1.16) by $0.21. Ionis Pharmaceuticals had a negative return on equity of 115.66% and a negative net margin of 44.90%. The business had revenue of $134.00 million during the quarter, compared to analysts’ expectations of $128.99 million. As a group, analysts forecast that Ionis Pharmaceuticals will post -3.73 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Commonwealth Equity Services LLC raised its stake in shares of Ionis Pharmaceuticals by 2.4% in the first quarter. Commonwealth Equity Services LLC now owns 21,974 shares of the company’s stock worth $953,000 after acquiring an additional 512 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Ionis Pharmaceuticals during the first quarter valued at $613,000. Grandfield & Dodd LLC boosted its holdings in Ionis Pharmaceuticals by 2.0% in the first quarter. Grandfield & Dodd LLC now owns 33,774 shares of the company’s stock valued at $1,464,000 after acquiring an additional 670 shares during the last quarter. SG Americas Securities LLC increased its position in Ionis Pharmaceuticals by 23.7% in the first quarter. SG Americas Securities LLC now owns 7,582 shares of the company’s stock worth $329,000 after purchasing an additional 1,453 shares during the period. Finally, Susquehanna Fundamental Investments LLC bought a new stake in Ionis Pharmaceuticals during the 1st quarter worth about $1,976,000. 93.86% of the stock is owned by institutional investors and hedge funds.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.